Sökning: L773:0025 7974 >
Effect on mother an...
Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome
-
- Gustavsen, Alice (författare)
- Norwegian Radium Hospital
-
- Skattum, Lillemor (författare)
- Lund University,Lunds universitet,Institutionen för laboratoriemedicin,Medicinska fakulteten,Department of Laboratory Medicine,Faculty of Medicine
-
- Bergseth, Grethe (författare)
- UiT The Arctic University of Norway, Tromsø
-
visa fler...
-
- Lorentzen, Bjorg (författare)
- Oslo university hospital
-
- Floisand, Yngvar (författare)
- Oslo university hospital
-
- Bosnes, Vidar (författare)
- Oslo university hospital
-
- Mollnes, Tom Eirik (författare)
- Norwegian University of Science and Technology,UiT The Arctic University of Norway, Tromsø,Norwegian Radium Hospital
-
- Barratt-Due, Andreas (författare)
- Oslo university hospital,Norwegian Radium Hospital
-
visa färre...
-
(creator_code:org_t)
- 2017
- 2017
- Engelska.
-
Ingår i: Medicine. - 0025-7974. ; 96:11
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Rationale: Antiphospholipid syndrome (APS) in pregnancy may trigger the life-threatening catastrophic antiphospholipid syndrome (CAPS). Complement activation is implicated in the pathogenesis, and inhibition of complement factor C5 is suggested as an additional treatment option. Patient concerns, diagnosis and interventions: We present a pregnant patient treated with the C5-inhibitor eculizumab due to high risk of developing devastating APS-related complications. The complement inhibitory effects of the treatment were examined both in the patient and the premature infant. Outcomes: Complement activity in the mother recovered considerably faster than anticipated; however, no new thrombosis or CAPS developed during the last week of pregnancy or postpartum. Blood sampling from the umbilical vein and artery, and from the infant after delivery showed low complement activity; however, only 0.3% of the eculizumab concentration detected in the mother, consistent with low placental passage of eculizumab. Lessons: The data underscore the importance of close monitoring of complement inhibition and individualizing dosage regimens in pregnant patients receiving eculizumab. We document how traditional functional complement activity tests cannot assess the effect of eculizumab in premature infants due to the very low levels of complement factors detected in this infant born in gestational week 33. Only trace amounts of eculizumab passed the placenta. In conclusion, complement C5 inhibition might be a safe candidate treatment option for APS during pregnancy and delivery, and additionally, enables prolongation of pregnancy with important weeks.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
Nyckelord
- antiphospholipid syndrome
- complement
- eculizumab
- pregnancy
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
-
Medicine
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas